Discounted Cash Flow (DCF) Analysis Unlevered

Jaguar Health, Inc. (JAGX)

$0.3082

+0.01 (+4.83%)
All numbers are in Millions, Currency in USD
Stock DCF: 19,403.55 | 0.3082 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 4.364.425.789.394.344.785.265.806.397.04
Revenue (%)
EBITDA -33.36-28.20-30.87-29.29-61.02-34.94-38.50-42.42-46.74-51.50
EBITDA (%)
EBIT -33.94-29.52-32.80-31.02-62.05-36.08-39.75-43.80-48.26-53.17
EBIT (%)
Depreciation 0.581.321.931.731.031.141.251.381.521.67
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash 0.522.573.508.0917.055.836.427.087.808.59
Total Cash (%)
Account Receivables 0.4711.692.101.711.191.311.441.591.75
Account Receivables (%)
Inventories 2.073.342.132.784.902.893.193.513.874.26
Inventories (%)
Accounts Payable 7.355.415.354.764.935.245.776.367.017.72
Accounts Payable (%)
Capital Expenditure --0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.3,082
Beta 1.814
Diluted Shares Outstanding 13.41
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt -193.90%
Risk-Free Rate
Market Risk Premium
Cost of Equity 11.453
Total Debt 4.34
Total Equity 4.13
Total Capital 8.47
Debt Weighting 51.25
Equity Weighting 48.75
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 4.364.425.789.394.344.785.265.806.397.04
EBITDA -33.36-28.20-30.87-29.29-61.02-34.94-38.50-42.42-46.74-51.50
EBIT -33.94-29.52-32.80-31.02-62.05-36.08-39.75-43.80-48.26-53.17
Tax Rate 37.50%0.00%-0.03%0.00%0.00%7.49%7.49%7.49%7.49%7.49%
EBIAT -21.21-29.52-32.81-31.02-62.05-33.37-36.77-40.51-44.64-49.19
Depreciation 0.581.321.931.731.031.141.251.381.521.67
Accounts Receivable --0.53-0.69-0.400.390.52-0.12-0.13-0.15-0.16
Inventories --1.271.21-0.65-2.122.01-0.29-0.32-0.36-0.39
Accounts Payable --1.94-0.06-0.590.170.310.530.590.650.71
Capital Expenditure --0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01
UFCF -20.63-31.95-30.43-30.95-62.59-29.41-35.41-39.02-42.99-47.37
WACC
PV UFCF -472.80-9,152.48-162,129.33-2,871,999.13-50,875,304.61
SUM PV UFCF -53,919,058.34

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -93.78
Free cash flow (t + 1) -48.31
Terminal Value 50.44
Present Value of Terminal Value 54,179,171.75

Intrinsic Value

Enterprise Value 260,113.40
Net Debt -12.71
Equity Value 260,126.11
Shares Outstanding 13.41
Equity Value Per Share 19,403.55